HIGHLIGHTS
SUMMARY
Previous KI-AE association Nature Communications | 13:4349 studies did not consider individualized drug exposure-AE response relationships, making it challenging to use the characterized KI-AE relationships to predict personalized TEAEs of an SMKI based on individual drug exposure and KIs. Consequently, the authors can construct a multi-domain, heterogeneous, and high-dimensional dataset integrating patient-level demographic, PK, and safety data, as well as nonclinical information such as in_vitro KI potency profiles of SMKIs. Review of AEs following SMKI treatments Out of the 65 SMKIs approved by the FDA up to December . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.